It’s taken LVMH nearly a year-and-a-half to regain its spot as Europe’s biggest stock from Novo Nordisk A/S.Most Read from ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy ... Other drugs up for 2027 ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate-modulating mechanism of ...

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 7 includes Village Super Market, MARA Holdings, ...

Brii said it agreed to purchase the assets from VBI Vaccines Inc. and its creditors for $18 million. The deal gives Brii full access to the remaining IP, patents and materials related to BRII-179, an ...

BMI OrganBank has secured a $3.5 million federal grant that will help the Winston-Salem company advance its kidney preservation technology and prepare for clinical trials.

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as the company's ...

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...